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S4 Diabetic Nephropathypollutants (POP) affects renal injury has not been elucidated. Perfluorooc-
tane sulfonate (PFOS) is an emerging POP in China. PFOS is readily absorbed
after oral exposure and accumulates primarily in the serum, kidney, and
liver. Toxicological studies on animals indicate its potential developmental,
reproductive and systematic effect. PFOS can activate peroxisome prolifer-
ator-activated receptor alpha (PPARalpha) and may act via PPARalpha to
produce some of their effects. In this study, we examined whether PFOS
enhanced renal injury in vitro under diabetic condition. Our results
demonstrated that the presence of PFOS was able to enhance the expression
of fibrotic markers and enhanced oxidative stress in renal tubular epithelial
cells under diabetic condition. PFOS also promoted the apoptosis of the
renal tubular epithelial cells. This study demonstrated that presence of PFOS
promoted renal injury in vitro under diabetic condition, suggesting that an
environmental pollutant is associated with renal injury in DNhttp://dx.doi.org/10.1016/j.hkjn.2015.08.014
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Objective: To evaluate the relationship between tubulointerstital injury and
hyperphosphatemia in the patients with type 2 diabetes and diabetic ne-
phropathy (T2DN), and investigate the association of hyperphosphatemia
with the renal outcome, especially in the T2DN patients with
eGFR60 ml/min per 1.73 m2.
Methods: A total of 396 patients with T2D and biopsy-proven DN from Nanj-
ing DN registration system who received follow-up for at least 1 year were
recruited and median 5-year follow-up. Renal outcomes were defined by
progression to end-stage renal disease and doubling of serum creatinine.
Results: Of the participants, the baseline eGFR was 73.86  33.52 mL/min
per 1.73 m2. The levels of the urinary tubulointerstitial injury markers
including the NAG, RBP and NAGL were significantly difference among quin-
tiles of serum phosphorus (P < 0.01). The participants whose eGFR90 ml/
min per 1.73 m2 had a higher rate of tubulointerstitial injury (interstitial
fibrosis tubular atrophy scores of 2 and 3, P Z 0.005; interstitial inflamma-
tion scores of 1 and 2, P Z 0.035) in hyperphosphatemia (>1.45 mmol/L)
group than in lower phosphorus group (<1.17 mmol/L). Participants with
baseline levels of serum phosphorus in higher quintiles had a higher cumula-
tive incidence of ESRD (log-rank, P < 0.01). In the analyses adjusted by age,
sex, diabetes status, BP, FBG, BMI, proteinuria, cholesterol, and eGFR, the
relationship between higher serum phosphorus and an increased risk of
ESRD remained. The association between serum phosphorus and ESRD risk
persisted and was stronger when the sample was restricted to those with a
baseline eGFR equal to 60e90 mL/min per 1.73 m2, but not when it was
restricted to patients with a baseline eGFR of 30e60 mL/min per 1.73 m2.
Conclusion: These findings indicated the baseline serum phosphorus is asso-
ciated with tubularinterstitial injury of T2DN. And serum phosphorus
>1.45 mmol/L is an independent risk factor of ESRD in T2DN, especially in
the patients with eGFR60 ml/min per 1.73 m2.http://dx.doi.org/10.1016/j.hkjn.2015.08.015
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Objective: Serum cystatin C is an alternative to serum creatinine for esti-
mating glomerular filtration rate (GFR), however, the utility of estimated
GFR from combination of serum creatinine and cystatin C as marker topredict long-term renal outcome is uncertain, particularly in the Type 2 dia-
betic nephropathy (DN).
Methods: A total of 501 patients (The National Clinical Research Center of
Kidney Diseases, 2003e2011) were recruited in prospective cohort study.
Follow-up was 5-year. Renal outcome was defined by eGFRcre-
cys < 15 ml/min per 1.73 m2 or renal replacement therapy.
Results: The distributions of standardized serum cystatin C with eGFRcre and
eGFRcre-cys are shown in Figure 1. Kaplan-Meier curves showed significantly
increased renal end points with higher quartile of cystatin C (p < 0.001) and
lower eGFRcre-cys (p < 0.001). The highest AUROCs was eGFRcre-cys in pre-
dicting the renal endpoint compared with eGFRcre or eGFRcys. The best cut-
off value for predicting the renal endpoint was 29.28% decline in the 24-
month, which value showed 79.6% sensitivity and 82.6% specificity. Cox
regression models with restricted cubic splines were shows a change of
30% in eGFRcre-cys was associated with adjusted HRs for ESRD of 27.92
(95%CI, 3.95e197.48) over 2-year.
Figure 1. The population of estimated GFRcre, GFRcys and GFRcre-cys
equation.
Conclusion: eGFRcre-cys was a precision, and accuracy marker in the pre-
dicting of the renal outcome and 30% decline of eGFRcre-cys over 2 years
was strongly associated with the risk of ESRD, suggesting it could be used
as an alternative end point in T2DN.http://dx.doi.org/10.1016/j.hkjn.2015.08.016
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Objective: Tangshen formula (TSF), as a traditional Chinese medicine, has
been shown to have good clinical efficacy in diabetic nephropathy (DN)
treatment. In this study, the potential molecular targets of TSF were
explored in db/db mice treated with TSF.
Methods: db/db mice were treated with or without TSF by gavage for
12 weeks, with db/m mice as a control. Serum glucose, 24h-albuminuria and
histology were detected. Gene expression microarray was carried to detected
the gene expression profile in 3 groups mice kidney tissues.
Results: The results showed that treatment with TSF significantly reduced
serum glucose and the excretion of urinary albumin in db/db mice, and
attenuated secretion of extracellular matrix in renal glomeruli. Clustering
analysis indicated the three groups could be their respective together for
a class and almost 400 differentially expressed genes were identified in
db/db mice and TSF-treated mice. These genes were mainly involved in
